All companies
Visit website
EYEDETEC MEDICAL
OperatingEyedetec Medical, Inc
Healthcare · Founded 2010
Chronic dry eye therapy reamigined
Post-money valuation ⓘ
$15.2M
As of Apr 2024 · from Eyedetec Medical Preferred Stock 1 · pre-money + amount raised, not a traded price
Total raised
$0
Across 1 round since 2024
Latest share price
$3.88
Eyedetec Medical Preferred Stock 1 offering price
Financials
FY2021–FY2022 · from SEC filings · hover any figure for its source$362K
−$884K
2021
$412K
−$635K
2022
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021
FY2022
Income statement
Revenue
$362,367
$411,720
Cost of goods sold
$180,311
$120,112
Gross margin
50%
71%
Net income
-$884,110
-$635,392
Taxes paid
$800
$0
Balance sheet
Cash
$407,228
$301,838
Accounts receivable
$17,385
$40,118
Total assets
$521,914
$451,362
Short-term debt
$703,247
$1,041,720
Long-term debt
$5,249,175
$5,475,542
Total liabilities
$5,952,422
$6,517,262
Other
Headcount
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$15.2M
post-money
Eyedetec Medical Preferred Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $0 / $1.2MInvestors 31Post-money $15.2M
Reg CF annual-report compliance
Not obligated
never closed a Reg CF raise
31 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001441817Share price $3.88
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.